SESSION TITLE: Cancer Case Report Posters II
SESSION TYPE: Case Report Poster
PRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PM
INTRODUCTION: Cisplatin, is a heavy metal complex which is used alone or with other cytotoxics,for long years in the treatment of solid tumors. Although renal and gastrointestinal toxicity are commonly dose limiting, several neurological complications have been described,particularly after high doses. The main neurological side effects are peripheral sensory neuropathy predominantly and ototoxicity, which may be irreversible. Seizures are rare and are often reversible.
CASE PRESENTATION: 55 years old male patient with a diagnosis of extensive stage small cell lung cancer received etoposide (100mg/m2) and cisplatin(75mg/m2). Just after the second day of fourth course of chemotherapy,long lasting life threatening grand mal seizure was occured. Investigations showed normal results of haematological and biochemical tests.The patient was referred to neurology suspicion of brain metastases. Brain MR and EEG was found normal. Cisplatin toxicity attributed to the clinical picture.
DISCUSSION: The incidence of seizures induced by cisplatin has been estimated at 10%, and they may occur from six hours to three months after treatment. At lung cancer, seizures are often seen due to brain metastases. However, several months after cisplatin treatment, convulsions or seizures may occur. Such patients may be wrongly assumed to have progressive disease.
CONCLUSIONS: We conclude that physicians using cisplatin chemotherapy should be aware of this rare complication.
Reference #1: Steeghs, N.a c; de Jongh, F. E.a d; Smitt, P. A. E. Sillevisb; Bent, M. J. van denb .Cisplatin-induced encephalopathy and seizures. Anti-Cancer Drugs. 2003 - Volume 14 - Issue 6 - pp 443-446 Case Report
Reference #2: Fuse-Nagase Y, Suwa K, Nagao Y.Partial seizures associated with cisplatin administration: a case report.Clin Electroencephalogr. 1997 Jan;28(1):55-6
DISCLOSURE: The following authors have nothing to disclose: Makbule Ozlem Akbay, Dilek Ernam, Nuray Erdal, Aysegul Cubuk
No Product/Research Disclosure Information